D

Raincatcher Represents Research Tool & Die on Its Successful Sale to Fairbanks Morse Defense

Retrieved on: 
Thursday, September 29, 2022

DENVER, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Research Tool & Die Works, Inc. (RT&D), a family-owned supplier of high-quality electrical hardware to the U.S. and Canadian Navies, has been acquired by Fairbanks Morse Defense.

Key Points: 
  • DENVER, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Research Tool & Die Works, Inc. (RT&D), a family-owned supplier of high-quality electrical hardware to the U.S. and Canadian Navies, has been acquired by Fairbanks Morse Defense.
  • Established in 1944 by Fred Perrault, ownership of the business later passed to son Ray Perrault and his wife Karen Perrault.
  • This is a marquise deal for me personally and for Raincatcher as a firm, said Aaron Linnebach, Managing Director at Raincatcher.
  • I do not doubt that under Fairbanks Morse Defense the next 75 years will be just as fruitful.

Cure Rare Disease Acquires Laboratory Space for New Headquarters in Connecticut

Retrieved on: 
Thursday, September 29, 2022

Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company, has acquired its first laboratory space at 4 Research Drive in Woodbridge, Connecticut, where the organization will relocate its headquarters and expand its research and development operations.

Key Points: 
  • Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company, has acquired its first laboratory space at 4 Research Drive in Woodbridge, Connecticut, where the organization will relocate its headquarters and expand its research and development operations.
  • CRD will also make 15,000 square feet of space available for lease to other life science and healthcare firms.
  • "AdvanceCT is thrilled to welcome Cure Rare Disease to Connecticut, said Tim Miller, Director of BD, Life Sciences, at AdvanceCT.
  • Cure Rare Disease, a 501(c)(3) nonprofit biotechnology company based in Boston, is transforming possibilities for people with rare diseases by developing advanced therapeutics in time to save lives.

Global 3D Medical Imaging Market Report (2022 to 2027) - Inclination of Radiologists Toward 3D Medical Imaging is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

The "3D Medical Imaging Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "3D Medical Imaging Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • 3D medical imaging is a technology that provides enlarged, in detail images of the interior body for medical analysis by utilizing 3D imaging modalities.
  • 3D medical imaging is a burgeoning market that is transforming radiological diagnosis and surgical planning.
  • Which region is expected to hold the largest share in the 3D medical imaging market?

Govenda Launches D&O Questionnaire Suite

Retrieved on: 
Wednesday, September 28, 2022

Govendas D&O Suite eliminates the need to navigate multiple systems, and automated or customizable reminders minimize the time spent prompting members to complete their questionnaires.

Key Points: 
  • Govendas D&O Suite eliminates the need to navigate multiple systems, and automated or customizable reminders minimize the time spent prompting members to complete their questionnaires.
  • D&O Suite offers the right blend of technology and included services to get companies up and running without expensive consultants and unnecessary delays.
  • Lewis continued, "Govenda's New D&O Suite includes everything in one system, instead of spread out across lots of emails and confusing network folders.
  • For more information about the Govenda D&O Suite, visit www.govenda.com/do-suite.

As part of its strategy for global growth and the enhancement of internal expertise, focusing on biotech, Olon is delighted to present its two-year plan for investment in the Settimo Torinese Biotech Centre (Italy)

Retrieved on: 
Wednesday, September 28, 2022

The investment will support a structured and focused plan with the aim of expanding capacity and capability to develop and produce therapeutic peptides obtained through biotechnology.

Key Points: 
  • The investment will support a structured and focused plan with the aim of expanding capacity and capability to develop and produce therapeutic peptides obtained through biotechnology.
  • Olon is developing strong know-how for the development of rDNA peptides and proteins, consolidating its expertise to produce the peptide target quickly and easily.
  • A second step involves creating a system designed for large volumes of peptides, typically indicated for diseases that are widespread throughout the world.
  • The investment will have significant impacts on employment and will involve the expansion of highly qualified roles, particularly in the strategic departments of quality, control, and research.

As part of its strategy for global growth and the enhancement of internal expertise, focusing on biotech, Olon is delighted to present its two-year plan for investment in the Settimo Torinese Biotech Centre (Italy)

Retrieved on: 
Wednesday, September 28, 2022

The investment will support a structured and focused plan with the aim of expanding capacity and capability to develop and produce therapeutic peptides obtained through biotechnology.

Key Points: 
  • The investment will support a structured and focused plan with the aim of expanding capacity and capability to develop and produce therapeutic peptides obtained through biotechnology.
  • Olon is developing strong know-how for the development of rDNA peptides and proteins, consolidating its expertise to produce the peptide target quickly and easily.
  • The goal is to further strengthen the offer to global clients in terms of complex recombinant peptides with high efficiency, repeatability, and purity, at high levels of consistency.
  • A second step involves creating a system designed for large volumes of peptides, typically indicated for diseases that are widespread throughout the world.

AION Labs Launches AI Startup Addressing Drug Trial Improvement

Retrieved on: 
Wednesday, September 28, 2022

REHOVOT, Israel, Sept. 28, 2022 /PRNewswire/ -- AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of OMEC.AI, the lab's first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the probability of success of drug candidates in clinical trials.

Key Points: 
  • In addition to funding, support and mentorship, AION Labs and its pharma partners will provide OMEC.AI with pharmaceutical data for model training and advanced machine learning development.
  • "With the support of AION Labs and its partners, we hope to develop a cutting-edge solution to significantly improve the probability of success of drug candidates that make it to the clinical trial phase."
  • OMEC.AI is the first startup to be formed by AION Labs, which creates early-stage startup teams that harness the power of artificial intelligence to transform the process of drug discovery and development for the betterment of human health.
  • "The formation of OMEC.AI is a significant milestone in our journey towards improving drug discovery and patient care through innovation," said Mati Gill, CEO of AION Labs.

FPT Industrial announces the acquisition of a minority stake in Blue Energy Motors

Retrieved on: 
Wednesday, September 28, 2022

FPT Industrial, the global powertrain brand of Iveco Group (MI: IVG), announces that it has entered into an agreement to make a minority investment in Blue Energy Commercial Vehicles Private Ltd, a zero-emission truck technology company headquartered in Pune, India, engaged in the manufacturing of clean energy trucks under the brand Blue Energy Motors.

Key Points: 
  • FPT Industrial, the global powertrain brand of Iveco Group (MI: IVG), announces that it has entered into an agreement to make a minority investment in Blue Energy Commercial Vehicles Private Ltd, a zero-emission truck technology company headquartered in Pune, India, engaged in the manufacturing of clean energy trucks under the brand Blue Energy Motors.
  • This follows the agreement announced in July for the supply of FPT Industrial natural gas engines to Blue Energy Motors, aimed at introducing the first Liquified Natural Gas (LNG) heavy-duty trucks to Indian roads by the end of this year.
  • At the beginning of September, Blue Energy Motors officially inaugurated its assembly plant in Chakan, Pune, India, and unveiled their first fully manufactured vehicles.
  • The investment further demonstrates the full support of FPT Industrial to the growth of Blue Energy Motors in its ambitious plan to play a key role in Indias decarbonisation transition.

Galapagos increases share capital through subscription right exercises

Retrieved on: 
Tuesday, September 27, 2022

Mechelen, Belgium; 27 September 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Key Points: 
  • Mechelen, Belgium; 27 September 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
  • Galapagos issued 107,000 new ordinary shares on 27 September 2022, for a total capital increase (including issuance premium) of EUR 3,076,250.
  • Pursuant to the subscription right exercise program for Galapagos executive committee, the members of the executive committee automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions.
  • In accordance with the rules of this program, one executive committee member exercised 5,000 subscription rights.

Marelli expands innovation capabilities with a new Technical R&D center in Bangalore

Retrieved on: 
Tuesday, September 27, 2022

BANGALORE, India, Sept. 27, 2022 /PRNewswire/ -- Marelli inaugurated its new Technical R&D Center in Bangalore, Southern India, further boosting the company's innovation capability, particularly in software engineering.

Key Points: 
  • BANGALORE, India, Sept. 27, 2022 /PRNewswire/ -- Marelli inauguratedits new Technical R&D Center in Bangalore, Southern India, further boosting the company's innovation capability, particularly in software engineering.
  • When fully operational, the new technical R&D center, together with the company's established engineering center in Gurugram (Delhi area), will increase Marelli India's R&D capability boosting its research team to more than 1,600 members.
  • The main activities of the Bangalore center will be focused on major technology areas of Marelli such as electronics, automotive lighting and both internal combustion powertrain and electric powertrain.
  • That's why further expanding Marelli's R&D capabilities is key to our success" said David Slump, President and CEO, Marelli.